243 related articles for article (PubMed ID: 23404221)
1. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer.
Saito S; Okabe H; Watanabe M; Ishimoto T; Iwatsuki M; Baba Y; Tanaka Y; Kurashige J; Miyamoto Y; Baba H
Oncol Rep; 2013 Apr; 29(4):1570-8. PubMed ID: 23404221
[TBL] [Abstract][Full Text] [Related]
2. Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer.
Mashita N; Yamada S; Nakayama G; Tanaka C; Iwata N; Kanda M; Kobayashi D; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y
J Surg Oncol; 2014 Nov; 110(6):745-51. PubMed ID: 24975268
[TBL] [Abstract][Full Text] [Related]
3. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
[TBL] [Abstract][Full Text] [Related]
4. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.
Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR
Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741
[TBL] [Abstract][Full Text] [Related]
5. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44v6 has no prognostic value in patients with colorectal cancer.
Jüngling B; Menges M; Goebel R; Wittig BM; Weg-Remers S; Pistorius G; Schilling M; Bauer M; König J; Zeitz M; Stallmach A
Z Gastroenterol; 2002 Apr; 40(4):229-33. PubMed ID: 11961731
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
9. Vimentin expression is associated with decreased survival in gastric cancer.
Otsuki S; Inokuchi M; Enjoji M; Ishikawa T; Takagi Y; Kato K; Yamada H; Kojima K; Sugihara K
Oncol Rep; 2011 May; 25(5):1235-42. PubMed ID: 21327330
[TBL] [Abstract][Full Text] [Related]
10. FMNL2 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition.
Li Y; Zhu X; Zeng Y; Wang J; Zhang X; Ding YQ; Liang L
Mol Cancer Res; 2010 Dec; 8(12):1579-90. PubMed ID: 21071512
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
12. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy.
Mima K; Hayashi H; Imai K; Kuroki H; Nakagawa S; Okabe H; Chikamoto A; Watanabe M; Beppu T; Baba H
J Hepatobiliary Pancreat Sci; 2013 Apr; 20(4):429-34. PubMed ID: 23238743
[TBL] [Abstract][Full Text] [Related]
13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.
Nagaraju GP; Long TE; Park W; Landry JC; Taliaferro-Smith L; Farris AB; Diaz R; El-Rayes BF
Mol Carcinog; 2015 Oct; 54(10):1147-58. PubMed ID: 24861206
[TBL] [Abstract][Full Text] [Related]
15. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients.
Matsushita K; Toiyama Y; Tanaka K; Saigusa S; Hiro J; Uchida K; Inoue Y; Kusunoki M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S518-27. PubMed ID: 21845497
[TBL] [Abstract][Full Text] [Related]
16. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
Gao ZH; Lu C; Wang ZN; Song YX; Zhu JL; Gao P; Sun JX; Chen XW; Wang MX; Dong YL; Xu HM
Histopathology; 2014 Oct; 65(4):527-38. PubMed ID: 24738665
[TBL] [Abstract][Full Text] [Related]
17. Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer.
Zhu Z; Zhu Z; Pang Z; Xing Y; Wan F; Lan D; Wang H
Int J Oncol; 2013 Apr; 42(4):1271-8. PubMed ID: 23403865
[TBL] [Abstract][Full Text] [Related]
18. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
20. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Garraway I; Wong SG; Belldegrun AS; Pantuck AJ
J Urol; 2010 Jun; 183(6):2403-8. PubMed ID: 20403620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
